ackground: Purified cannabidiol (CBD) was administered to highly refractory patients with Dravet (DS) or Lennox-Gastaut (LGS) syndromes in an ongoing expanded access program (EAP). Herein, we report interim results on CBD safety and seizure outcomes in patients treated for a 12-month period.
Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome / Iannone, L.F., Arena, G., Battaglia, D., Bisulli, F., Bonanni, P., Boni, A., Canevini, M.P., Cantalupo, G., Cesaroni, E., Contin, M., Coppola, A., Cordelli, D.M., Cricchiuti, G., De Giorgis, V., De Leva, M.F., De Rinaldis, M., d'Orsi, G., Elia, M., Galimberti, C.A., Morano, A., et al.. - In: FRONTIERS IN NEUROLOGY. - ISSN 1664-2295. - ELETTRONICO. - 12:(2021), pp. 0-0. [10.3389/fneur.2021.673135]
Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome
Iannone, Luigi Francesco;Guerrini, Renzo;
2021
Abstract
ackground: Purified cannabidiol (CBD) was administered to highly refractory patients with Dravet (DS) or Lennox-Gastaut (LGS) syndromes in an ongoing expanded access program (EAP). Herein, we report interim results on CBD safety and seizure outcomes in patients treated for a 12-month period.
| File | Dimensione | Formato | |
|---|---|---|---|
|
fneur-12-673135.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
646.67 kB
Formato
Adobe PDF
|
646.67 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
